seven

“Phal-501 can be a great drug that has the potential to change the lives of many patients with severe COPD.”

Welcome to PharmaLundensis!

PharmaLundensis develops drugs that bind and excrete heavy metals such as mercury, lead and cadmium from the body. This is expected to bring significant health improvements in a number of diseases.

Phal-501 binds methylmercury very effectively

Methylmercury fits like a glove on the Phal-501, which is visible both from above and from the
side. Sulfur has a very strong tendency to bind to mercury. Five sulfur atoms surround the
mercury atom, creating an extremely strong bond.

Read more

Function and benefits of Phal-501

Phal-501 provides a strong and long-lasting binding of mercury and probably also lead and cadmium. Furthermore, Phal-501 is expected to have very small side effects, if any, as the substance never enters the bloodstream. After swallowing, Phal-501 binds heavy metals in the intestine and then goes directly into the stool. This allows the body’s heavy metals to be “leached out” and rendered harmless.

Read more

News

Publication of rights issue material

PharmaLundensis rights issue is available 13 -27 february. Message from the CEO Memorandum Feb 2025...

Carries out a rights issue of up to approx. MSEK 14.4

PharmaLundensis press release ENG At the board meeting of PharmaLundensis AB (publ) (“PharmaLundensis” or the...

Positive results in animal toxicology tests with Phal-501

The pilot animal toxicology study with Phal-501 in mice has now been completed. The study...

There is much to suggest that depression is also caused by one or more heavy metals, and that the disorder should therefore be treated with drugs that excrete heavy metals from the body.